Management Team

President and director john sperzel

John Sperzel
President and Chief Executive Officer

John J. Sperzel joined Chembio Diagnostic Systems, Inc. in March 2014, and serves as President and Chief Executive Officer (CEO) and as a member of the Board of Directors. Prior to joining the company, Mr. Sperzel served as President and CEO at ITC, a Point of Care Diagnostics company owned by Warburg Pincus. He previously held executive leadership positions at Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim. Mr. Sperzel received a B.S. in Business Administration/Management from Plymouth State College and serves as an advisor to the Board of the Diagnostic Marketing Association.

Executive Officer Neil A. Goldman, CPA

Neil A. Goldman, CPA
Executive Vice President,
Chief Financial Officer

Mr. Goldman joined Chembio in December 2017. Most recently, he served as Executive VP-Corporate Development & CFO of J.S. Held, a private equity-sponsored national consulting firm. Previously, he held EVP, COO, and CFO positions at Unwired Technology and then joined Delphi Corp., now Aptiv plc (NYSE: APTV), as a Global Finance Director following Delphi’s acquisition of Unwired. Unwired was a tier-1 automotive electronics manufacturer and portfolio company of American Capital. Prior to Unwired, Mr. Goldman served as CFO of EPPCO Enterprises. From 1989 to 2002, he worked as an auditor and advanced into regional and national management consulting roles at Ernst & Young and Cap Gemini Ernst & Young. Mr. Goldman received a B.S. in Business-Accountancy from Miami University, Oxford, OH.

Executive Officer Javan Esfandiari

Javan Esfandiari
Executive Vice President,
Chief Science and Technology Officer

Javan Esfandiari joined Chembio Diagnostic Systems, Inc. in February 2000, and serves as Chief Science and Technology Officer. Prior to joining the company, Mr. Esfandiari co-founded Sinovus Biotech AB, a Swedish biotech company where he served as Director of R&D until Chembio acquired Sinovus. He previously served as Director of R&D for On-Site Biotech. Mr. Esfandiari is the inventor of Chembio’s patented Dual Path Platform (DPP®) technology and developed more than 30 rapid point-of-care diagnostic products in the human and veterinary fields. Mr. Esfandiari received a B.S. in Clinical Chemistry and studied to M. Sc. Level in Molecular Biology from Lund University, Sweden.

Executive Officer David Gyorke

David Gyorke
Senior Vice President,
Chief Operations Officer

David Gyorke joined Chembio Diagnostic Systems, Inc. in January 2017. Mr. Gyorke has responsibility for Manufacturing and Operations for the Medord, NY and Kuala Lumpur, Malaysia factories. Prior to joining the company, Mr. Gyorke held VP of Operations positions, with Nanomix, NeoVista, and Cholestech (Alere). He received his Bachelors of Engineering (Industrial) at California Polytechnic State University.

President, EMEA and APAC Regions Robert Passas Ph.D.

Robert Passas Ph.D.
Senior Vice President,
Chief Commercial Officer

Robert Passas joined Chembio Diagnostic Systems, Inc. in October 2016, and serves as the Chief Commercial Officer where he is responsible for global sales, marketing, and customer support functions. Prior to joining the company, Dr. Passas served as Vice President, Worldwide Marketing and International Sales at Trinity Biotech. He previously held executive leadership positions with Abbott, Quidel, and The Binding Site. Dr. Passas received a B.S. in Medical Biochemistry and a Ph.D. in Analytical Chemistry from the University of Surrey, UK.

Executive Officer Tom Ippolito

Tom Ippolito
Vice President,
Quality and Regulatory Affairs

Tom Ippolito joined Chembio Diagnostic Systems, Inc. in June 2005, and serves as Vice President, Quality and Regulatory Affairs. Prior to joining the company, Mr. Ippolito served as Vice President, Regulatory and Quality at Biospecifics Technologies. He previously held a number of positions with United Biomedical, Biospecifics, Merck, Rhone Merieux, Organon Teknika, Analytab Products Inc., and Olympus. Mr. Ippolito holds the position of Course Director of the Fundamentals of Bioscience Program at the State University of Stony Brook and is the instructor for clinical development and regulatory affairs.

Executive Officer Paul Lambotte

Paul Lambotte
Vice President,
Research and Development

Paul Lambotte joined Chembio Diagnostic Systems, Inc. in December 2014, and serves as Vice President of Product Development. Prior to joining the company, Mr. Lambotte was President of PLC Inc., a POC product development consulting company. He previously served as Chief Science Officer at Axxin Pty Ltd, held positions of VP of R&D and Business Development at Quidel Corporation, and held a number of positions at Beckman Coulter and Hybritech Inc. Mr. Lambotte is the inventor of several patents in the field of rapid, point-of-care diagnostic products. He received a Master in Biochemistry and a PhD in Protein Biochemistry from the University of Mons, Belgium, and did post-doctoral work at the Ludwig Institute for Cancer research in Brussels, Belgium.

Christine M. Rousseau, Ph.D.

Christine M. Rousseau, Ph.D.
Vice President,
Corporate Development

Christine M. Rousseau, Ph.D. joined Chembio Diagnostics Systems, Inc. in July of 2018 as Vice President, Corporate Development. Prior to joining Chembio, Dr. Rousseau spent nine years at the Bill & Melinda Gates Foundation, most recently serving as Senior Program Officer, Global Health, Integrated Technology Solutions. While there, she directed over $250 million in assets for the development, commercialization, and scale-up of immune, molecular and cellular diagnostic technologies, including a significant role in HIV Self-Testing. Previously, Dr. Rousseau spent ten years as a research scientist and faculty member at the University of Washington, with emphasis in the areas of HIV and HCV. Earlier in her career, she was a Senior Fellow at the Fred Hutchinson Cancer Research Center and HIV Director & Founding Board Member of the Sustainable Sciences Institute.